Figure 3.

PARIS clinical study 2. The study evaluated the clinical impact of the combined use of real-time CGM (Guardian RT) together with telemedicine in insulin pump–treated (DTRON plus) type 1 diabetic subjects, integrated in the TAP. Insulin data were retrieved directly from the DTRON, plus insulin pump real-time CGM was used 3 days per week during the experimental phase. SMBG was used at all other times during both control and experimental phases. Data were available on the web and the patient's SA (iPAQ), which communicated with the DiabTel server.